The estimated Net Worth of L Daniel Browne is at least $4.98 Million dollars as of 15 March 2019. L Browne owns over 11,613 units of Revance Therapeutics Inc stock worth over $994,850 and over the last 11 years L sold RVNC stock worth over $3,980,217.
L has made over 18 trades of the Revance Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently L sold 11,613 units of RVNC stock worth $180,118 on 15 March 2019.
The largest trade L's ever made was selling 32,000 units of Revance Therapeutics Inc stock on 22 May 2017 worth over $649,280. On average, L trades about 6,455 units every 44 days since 2014. As of 15 March 2019 L still owns at least 151,193 units of Revance Therapeutics Inc stock.
You can see the complete history of L Browne stock trades at the bottom of the page.
L's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK, CA, 94560.
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli, and Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
Revance Therapeutics Inc executives and other stock owners filed with the SEC include: